AT290528B - Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen - Google Patents

Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen

Info

Publication number
AT290528B
AT290528B AT1082569A AT1082569A AT290528B AT 290528 B AT290528 B AT 290528B AT 1082569 A AT1082569 A AT 1082569A AT 1082569 A AT1082569 A AT 1082569A AT 290528 B AT290528 B AT 290528B
Authority
AT
Austria
Prior art keywords
pyrazin
imidazo
chloro
ones
salts
Prior art date
Application number
AT1082569A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of AT290528B publication Critical patent/AT290528B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT1082569A 1968-11-20 1969-11-19 Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen AT290528B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77747868A 1968-11-20 1968-11-20

Publications (1)

Publication Number Publication Date
AT290528B true AT290528B (de) 1971-06-11

Family

ID=25110370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT1082569A AT290528B (de) 1968-11-20 1969-11-19 Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen

Country Status (10)

Country Link
US (1) US3567725A (de)
AT (1) AT290528B (de)
BE (1) BE741910A (de)
BR (1) BR6914329D0 (de)
DE (2) DE1965989A1 (de)
FR (1) FR2035817B1 (de)
GB (1) GB1246006A (de)
IL (1) IL33336A0 (de)
NL (1) NL6915957A (de)
ZA (1) ZA698081B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810933D0 (en) * 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) * 1987-05-26 1988-06-15 Ici America Inc Amides
US5705585A (en) * 1993-06-30 1998-01-06 Arqule, Inc. Aminimide-containing molecules and materials as molecular recognition agents
AU704878B2 (en) * 1994-01-05 1999-05-06 Arqule, Inc. Method of making polymers having specific properties
US7034110B2 (en) * 1994-01-05 2006-04-25 Arqule, Inc. Method of identifying chemical compounds having selected properties for a particular application
US5734082A (en) * 1994-10-20 1998-03-31 Arqule Inc. Hydroxyethyl aminimides
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
WO1996031263A1 (en) * 1995-04-06 1996-10-10 Arqule, Inc. Method for rapid purification, analysis and characterization of collections of chemical compounds
US5962412A (en) * 1996-06-10 1999-10-05 Arqule, Inc. Method of making polymers having specific properties
EP2078016B1 (de) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2751705T3 (es) 2009-10-26 2020-04-01 Signal Pharm Llc Métodos de síntesis y purificación de compuestos heteroarilo
MX384385B (es) 2011-10-19 2025-03-14 Signal Pharm Llc Tratamiento del cancer con inhibidores de tor cinasa
JP6076370B2 (ja) 2011-12-02 2017-02-08 シグナル ファーマシューティカルズ,エルエルシー 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((トランス)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンの薬剤組成物、その固体形態、およびその使用方法
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR094494A1 (es) 2013-01-16 2015-08-05 Signal Pharm Llc Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (de) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmazeutische formulierungen von 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)-pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on
EP2986319A1 (de) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Kombinationstherapie mit einem torkinaseinhibitor und n-(3-(5-fluor-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamid zur behandlung von krebs
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ,エルエルシー 1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Also Published As

Publication number Publication date
FR2035817B1 (de) 1973-01-12
GB1246006A (en) 1971-09-15
FR2035817A1 (de) 1970-12-24
DE1965989A1 (de) 1971-02-18
US3567725A (en) 1971-03-02
DE1957711A1 (de) 1970-06-18
NL6915957A (de) 1970-05-22
IL33336A0 (en) 1970-01-29
BE741910A (de) 1970-05-19
ZA698081B (en) 1971-07-28
BR6914329D0 (pt) 1973-02-22

Similar Documents

Publication Publication Date Title
AT290528B (de) Verfahren zur Herstellung von neuen 5-NR&lt;1&gt;R&lt;2&gt;-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen
AT294113B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-2H-1,2-benzothiazin-1,1-dioxyden und ihren Salzen
AT295511B (de) Verfahren zur Herstellung von neuen Phenoxyaminopropanolderivaten und ihren Salzen
AT310158B (de) Verfahren zur Herstellung von neuen 2-(Thienyl-3&#39;-amino)-1,3-diazacycloalkenen-(2) und ihren Salzen
AT321277B (de) Verfahren zur Herstellung von neuen 1,3-Diphenyl-propan-1-onen und ihren Salzen
AT288378B (de) Verfahren zur Herstellung von neuen 1,2,5-Thiadiazolderivaten und ihren Salzen
AT303053B (de) Verfahren zur Herstellung von neuen 1,1,1-Trichloräthan-Derivaten und ihren Salzen
AT291250B (de) Verfahren zur Herstellung von neuen 5-NR&lt;1&gt;R&lt;2&gt; -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen
AT286290B (de) Verfahren zur Herstellung von neuen Pyridoindolderivaten und ihren Salzen
AT269166B (de) Verfahren zur Herstellung von neuen p,p&#39;-Dialkanoyldiphenylharnstoff-bis-guanylhydrazonen und ihren Salzen
AT299193B (de) Verfahren zur Herstellung von neuen Imidazolidinochinalinderivaten und ihren Salzen
AT289789B (de) Verfahren zur Herstellung von neuen 1,2,5-Thiadiazolderivaten und ihren Salzen
AT315862B (de) Verfahren zur Herstellung von neuen Diazepinderivaten und ihren Additionssalzen
AT286289B (de) Verfahren zur Herstellung von neuen Pyridoindolderivaten und ihren Salzen
AT287694B (de) Verfahren zur Herstellung von neuen Imidazolindinderivaten und ihren Salzen
AT295756B (de) Verfahren zur Herstellung von neuen Steroid-17&amp;alpa;,21-orthocarbonaten
AT288416B (de) Verfahren zur Herstellung von neuen Benzoxazinderivaten und ihren Salzen
AT307399B (de) Verfahren zur Herstellung von neuen basischen Dithienylpropen-Derivaten und ihren Salzen
AT315855B (de) Verfahren zur Herstellung von neuen basisch substituierten 2,3,7,8-Tetrahydro-1H-chino[1,8-ab][1]benzazepinen und von ihren Salzen
AT286299B (de) Verfahren zur herstellung von neuen 1-substituierten 6,7-dimethoxy-isochinolinen und ihren salzen
AT304488B (de) Verfahren zur Herstellung von neuen 9-Aminoalkyl-9,10-dihydro-9,10-äthano-anthrazenen und ihren Salzen
AT294112B (de) Verfahren zur Herstellung von neuen 3-Aryl-benzazinen und ihren Salzen
AT303749B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-oxathiazin-4-on-2,2-dioxyden und ihren Salzen
AT299196B (de) Verfahren zur Herstellung von neuen 5-Aryl-3H-1,2,4-dithiazolen und ihren Salzen
AT285620B (de) Verfahren zur Herstellung von neuen 1,2-Oxazinderivaten und ihren Salzen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee